Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy
Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy
About this trial
This is an interventional other trial for Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy focused on measuring Breast Cancer, Aromatase Inhibitor Therapy, Baduanjin Exercise
Eligibility Criteria
Inclusion Criteria:
- Have been diagnosed as stage I to III breast cancer 0.5 to 4.0 years before enrollment
- Taking an AI (aromatase inhibitors ),and had been receiving an AI for at least 6 months
Exclusion Criteria:
- A prior history of breast or any other cancer except basal or squamous cell skin cancer Inflammatory breast cancer
- With exercise contraindications:chronic obstructive pulmonary disease, uncontrolled hypertension, evidence of liver or kidney failure, symptomatic ischemic heart disease ,conditions involving the immune system such as autoimmune and/or inflammatory diseases, cognitive impairment, alcohol/drug abuse
- Current Baduanjin practice (within the last 6 months), and/or previous Baduanjin practice for more than 3 months
- Women reporting 5 hours or more of vigorous physical activity per week
Sites / Locations
- Guangdong General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Exercise group
Waiting list Control group
After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise. After their post-assessment they were able to attend the Baduanjin classes.